Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
In development
Reference number: GID-TA10391
Expected publication date: TBC
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lenadogene nolparvovec for treating Leber hereditary optic neuropathy.
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.